PA8453601A1 - Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer - Google Patents

Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer

Info

Publication number
PA8453601A1
PA8453601A1 PA19988453601A PA8453601A PA8453601A1 PA 8453601 A1 PA8453601 A1 PA 8453601A1 PA 19988453601 A PA19988453601 A PA 19988453601A PA 8453601 A PA8453601 A PA 8453601A PA 8453601 A1 PA8453601 A1 PA 8453601A1
Authority
PA
Panama
Prior art keywords
hmg coa
inhibitors
coa reductase
cancer treatment
combined
Prior art date
Application number
PA19988453601A
Other languages
English (en)
Inventor
Shama Mohammed Kajiji
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8453601A1 publication Critical patent/PA8453601A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN PROCEDIMIENTO PARA TRATAR CANCER EN UN MAMIFERO, INCLUIDO UN SER HUMANO, ADMINISTRANDO AL CITADO MAMIFERO UN INHIBIDOR DE LA FTASA COMBINADO CON UN INHIBIDOR DE LA HMG COA REDUCTASA.
PA19988453601A 1997-06-16 1998-06-15 Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer PA8453601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4963897P 1997-06-16 1997-06-16

Publications (1)

Publication Number Publication Date
PA8453601A1 true PA8453601A1 (es) 2000-05-24

Family

ID=21960890

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19988453601A PA8453601A1 (es) 1997-06-16 1998-06-15 Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer

Country Status (37)

Country Link
EP (1) EP0986387B1 (es)
JP (1) JP3713051B2 (es)
KR (1) KR100392573B1 (es)
CN (1) CN1259868A (es)
AP (1) AP9801261A0 (es)
AR (1) AR013090A1 (es)
AT (1) ATE235905T1 (es)
BG (1) BG103946A (es)
BR (1) BR9810616A (es)
CA (1) CA2294399C (es)
CO (1) CO4950607A1 (es)
DE (1) DE69812933T2 (es)
DK (1) DK0986387T3 (es)
DZ (1) DZ2518A1 (es)
EA (1) EA199901043A1 (es)
ES (1) ES2196559T3 (es)
GT (1) GT199800081A (es)
HN (1) HN1998000091A (es)
HR (1) HRP980328B1 (es)
HU (1) HUP0004624A3 (es)
ID (1) ID23014A (es)
IL (1) IL132765A0 (es)
IS (1) IS5259A (es)
MA (1) MA24569A1 (es)
NO (1) NO996206L (es)
NZ (1) NZ500662A (es)
OA (1) OA11231A (es)
PA (1) PA8453601A1 (es)
PE (1) PE82899A1 (es)
PL (1) PL337651A1 (es)
PT (1) PT986387E (es)
SK (1) SK169699A3 (es)
TN (1) TNSN98088A1 (es)
TR (1) TR199903074T2 (es)
UA (1) UA57081C2 (es)
WO (1) WO1998057633A1 (es)
ZA (1) ZA985182B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200000660A (et) * 1998-05-12 2002-04-15 Warner-Lambert Company Valk farnesüültransferaasi ja HMG CoA reduktaasi inhibiitorite kombinatsioonid ja nende kasutamine vähi raviks
WO2000016778A1 (en) * 1998-09-24 2000-03-30 Merck & Co., Inc. A method of treating cancer
EP1006113A1 (en) * 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
BR0116302A (pt) 2000-12-19 2004-01-13 Pfizer Prod Inc Formas cristalinas de sais 2,3-dihidroxibutanodioato de 6-[(4-clorofenil)-hidróxi-(3-metil-3h-imidazol-4-il)-meti l]-4-(3-etinil-fenil)-1-metil-1h-quinolin-2-ona e método de produção
CA2432642A1 (en) 2000-12-21 2002-08-08 Subhash P. Khanapure Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
JP2005200419A (ja) * 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0856315B1 (en) * 1995-08-09 2005-08-24 Banyu Pharmaceutical Co., Ltd. Protein-farnesyltransferase inhibitors in combination with hmgcoa-reductase-inhibitors for the treatment of aids

Also Published As

Publication number Publication date
WO1998057633A1 (en) 1998-12-23
HN1998000091A (es) 1999-09-29
JP2000513031A (ja) 2000-10-03
SK169699A3 (en) 2000-06-12
PE82899A1 (es) 1999-08-26
CA2294399A1 (en) 1998-12-23
NO996206L (no) 2000-02-15
AU724676B2 (en) 2000-09-28
AR013090A1 (es) 2000-12-13
TNSN98088A1 (fr) 2005-03-15
ES2196559T3 (es) 2003-12-16
DE69812933T2 (de) 2003-11-06
JP3713051B2 (ja) 2005-11-02
DK0986387T3 (da) 2003-07-14
NZ500662A (en) 2001-10-26
AU7445998A (en) 1999-01-04
BG103946A (bg) 2000-07-31
AP9801261A0 (en) 1999-12-11
DE69812933D1 (de) 2003-05-08
HRP980328A2 (en) 1999-04-30
IL132765A0 (en) 2001-03-19
CN1259868A (zh) 2000-07-12
EP0986387A1 (en) 2000-03-22
HRP980328B1 (en) 2002-06-30
ID23014A (id) 1999-12-30
HUP0004624A3 (en) 2002-11-28
BR9810616A (pt) 2000-09-12
ZA985182B (en) 1999-12-17
IS5259A (is) 1999-11-19
CO4950607A1 (es) 2000-09-01
PT986387E (pt) 2003-06-30
EA199901043A1 (ru) 2000-06-26
EP0986387B1 (en) 2003-04-02
MA24569A1 (fr) 1998-12-31
UA57081C2 (uk) 2003-06-16
PL337651A1 (en) 2000-08-28
KR100392573B1 (ko) 2003-07-23
ATE235905T1 (de) 2003-04-15
NO996206D0 (no) 1999-12-15
KR20010013839A (ko) 2001-02-26
TR199903074T2 (xx) 2000-05-22
OA11231A (en) 2003-05-26
DZ2518A1 (fr) 2003-02-01
HUP0004624A2 (hu) 2001-10-28
GT199800081A (es) 1999-12-07
CA2294399C (en) 2004-03-16

Similar Documents

Publication Publication Date Title
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
DK1169060T3 (da) Natriumkanalblokkerpræparater og anvendelse deraf
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
IL143901A0 (en) Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
DE69124371D1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
UY26815A1 (es) Métodos para tratar enfermedades reumáticas al usar una molécula ctla4 soluble
BR9805544A (pt) Uso de um composto.
DE59611341D1 (de) Verwendung von saccharid-konjugaten
CY1105788T1 (el) Χρηση του taci σαν παραγοντα καταπολεμησης ογκων
PA8453601A1 (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer
UY26929A1 (es) Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
MY138883A (en) Use of asiatic acid for treatment of cencer
TR199901104T2 (xx) Farmas�tik bile�ikler.
DE60039730D1 (de) Genetisch manipulierte Herpesviren zur Behandlung von Tumoren
DE60027905D1 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
MX9805290A (es) Utilizacion de inhibidores de la actividad del acido retinoico para tratar las pieles sensibles y/o los daños agudos inducidos por las radiaciones ultravioleta.
GB9907571D0 (en) Compounds
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
SE0100684D0 (sv) New subject-matter
MXPA02004699A (es) Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
ECSP982539A (es) INHIBIDORES DE LA FARNESIL TRANSFERASA COMBINADOS CON INHIBIDORES DE LA HMG CoA REDUCTASA PARA EL TRATAMIENTO DEL CANCER
IL139144A0 (en) Mycobacterial inhibitors
DK0720597T3 (da) Triarylethylenderivater til terapeutisk anvendelse
AU5434899A (en) Cancer treatment